JPRN-UMIN000022155已完成未知
Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease - STHENIC trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Type 1 diabetes 2) Severe diabetic complications such as ketoacidosis 3) Severe renal dysfunction(estimated glomerular filtration rate [eGFR] < 30 mL/min/) 4) Pregnant or nursing women and those who might be pregnant 5) Chronic heart failure, 6) Haemodialysis, 7) A history of stroke and cardiovascular events, 8) Any patient whom the investigator judged to be inappropriate for this study. Patients were given detailed explanations of the study protocol.
研究者
相似试验
尚未招募
不适用
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic NephropathyEffect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic NephropathyNCT06668753Assiut University114
已完成
不适用
Effect of high dose SGLT-2 inhibitor on fatty livertype2 diabetes/fatty liverJPRN-UMIN000047270Konuma Internal medicine Gastroenterology Clinic directer20
尚未招募
3 期
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusFatty Liver, NonalcoholicNCT06117137Sohag University150
尚未招募
3 期
Effect of Saroglitazar in Non alcoholic fatty liver diseaseCTRI/2024/03/063735o sponsor
已完成
不适用
Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitisJPRN-UMIN000018814Yokohama City University Graduate School of Medicine20